JPRN-jRCT2080222084未知1 期
Phase I study of YHI-1003 monotherapy in patients with relapsed or refractory neuroblastoma
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 2age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1)Patients were previously diagnosed with neuroblastoma
- •(2)Patients must have relapsed or refracted against the standard therary
排除标准
- •(1)Patients were previously treated with Perifosine.
研究者
相似试验
未知
2 期
Phase II trial of YHI-1003JPRN-jRCT2080222238Yakult Honsha Co., Ltd.96
未知
1 期
A phase I study of YHI-1001JPRN-jRCT2080221834Yakult Honsha Co., Ltd.18
未知
1 期
Phase I trial of YHI-1003 plus Bortezomib and DexamethasoneRelapsed Multiple Myeloma previously treated with BortezomibJPRN-jRCT2080221706Yakult Honsha Co., Ltd.18
进行中（未招募）
1 期
A study in patients with Myelodysplastic SyndromesMyelodysplastic SyndromesMedDRA version: 14.1Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2013-003235-30-ESilly S.A.140
进行中（未招募）
1 期
A study in patients with Myelodysplastic SyndromesMyelodysplastic SyndromesMedDRA version: 14.1Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851EUCTR2013-003235-30-ITEli Lilly and Company43